Large-scale testing (Phase 3)UnknownNCT01352091What this trial is testingAdjuvant AI Combined With ZoladexWho this might be right forBreast Cancer Fudan University 670
Large-scale testing (Phase 3)WithdrawnNCT06585969What this trial is testingA Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWho this might be right forMetastatic Breast CancerER-positive Breast CancerLuminal B+2 more Danish Breast Cancer Cooperative Group
Testing effectiveness (Phase 2)UnknownNCT01266213What this trial is testingFulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenWho this might be right forMetastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal Samsung Medical Center 147
Large-scale testing (Phase 3)Study completedNCT00390455What this trial is testingFulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveWho this might be right forEstrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559What this trial is testingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerWho this might be right forBreast Cancer Fudan University 189
Testing effectiveness (Phase 2)Study completedNCT00755885What this trial is testingAbiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Cancer Research UK 77
Early research (Phase 1)Active Not RecruitingNCT05509790What this trial is testingLY3484356 in Chinese Participants With Advanced Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 17
Testing effectiveness (Phase 2)Study completedNCT01234857What this trial is testingRidaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)Who this might be right forBreast Cancer Merck Sharp & Dohme LLC 115
Not applicableEnded earlyNCT02149173What this trial is testingF-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyWho this might be right forEstrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7 University of Washington 29
Testing effectiveness (Phase 2)Study completedNCT01421472What this trial is testingA Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerWho this might be right forER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients Merrimack Pharmaceuticals 196
Not applicableStudy completedNCT00115505What this trial is testingQuality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast CancerWho this might be right forBreast Carcinoma Alliance for Clinical Trials in Oncology 307
Testing effectiveness (Phase 2)Looking for participantsNCT07340541What this trial is testingEvolutionary Clinical Trial for Novel Biomarker-Driven TherapiesWho this might be right forBreast CancerMetastatic Breast CancerTriple Negative Breast Cancer+2 more UNC Lineberger Comprehensive Cancer Center 700
Testing effectiveness (Phase 2)Ended earlyNCT02395627What this trial is testingReversing Therapy Resistance With Epigenetic-Immune ModificationWho this might be right forBreast Neoplasms University of California, San Francisco 38
Not applicableUnknownNCT05814224What this trial is testingMonitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNAWho this might be right forHormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287098What this trial is testingImlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 600
Large-scale testing (Phase 3)Study completedNCT00002967What this trial is testingOctreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast CancerWho this might be right forBreast Cancer NSABP Foundation Inc
Testing effectiveness (Phase 2)WithdrawnNCT02853071What this trial is testingEfficacy and Safety of Estracyt® in Metastatic Breast CancerWho this might be right forBreast Cancer Centre Hospitalier Universitaire de Besancon
Not applicableEnded earlyNCT03619044What this trial is testingThe Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.Who this might be right forHER2-positive Breast Cancer Institut Claudius Regaud 4
Early research (Phase 1)Study completedNCT02219789What this trial is testingAlisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryWho this might be right forEstrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more Mayo Clinic 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774What this trial is testingPD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerWho this might be right forBreast Neoplasms Washington University School of Medicine 84